发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (Humulus lupulus L.). 黄腐酚:一种从啤酒花(Humulus lupulus L.)中提取的烯基化chalconoid。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-15 DOI: 10.4155/ppa-2020-0026
Diwakar Aggarwal, Sushil K Upadhyay, Raj Singh, Hardeep S Tuli
{"title":"Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (<i>Humulus lupulus</i> L.).","authors":"Diwakar Aggarwal,&nbsp;Sushil K Upadhyay,&nbsp;Raj Singh,&nbsp;Hardeep S Tuli","doi":"10.4155/ppa-2020-0026","DOIUrl":"https://doi.org/10.4155/ppa-2020-0026","url":null,"abstract":"<p><p>There is expanding proof that specific natural compounds found in plants have additional conventional medicinal properties. One such compound is xanthohumol (XN), which is being explored as an antimicrobial, anticarcinogenic, antidiabetic and anti-inflammatory agent - aside from its utilization in dealing with conditions like autism, bone and skin improvement and microbial infections, lipid-related illnesses, and so on. XN is reported to suppress the uncontrolled production of inflammatory mediators responsible for diseases including cardiovascular disease, neurodegeneration and tumors. Further, it is accounted to limit adipogenesis and control obesity by focusing on principal adipocyte marker proteins. It is most generally utilized in the brewing industry as an additive and flavoring agent to add bitterness and aroma to beer. Present investigation sum up the patents filed in most recent 2 years on development of different pharmaceutical mixes and strategies dependent on various therapeutic potentials of XN.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38740706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Mnk inhibitors: a patent review. 锰酸盐抑制剂:专利审查。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-14 DOI: 10.4155/ppa-2020-0028
Ahmed M Abdelaziz, Mingfeng Yu, Shudong Wang
{"title":"Mnk inhibitors: a patent review.","authors":"Ahmed M Abdelaziz,&nbsp;Mingfeng Yu,&nbsp;Shudong Wang","doi":"10.4155/ppa-2020-0028","DOIUrl":"https://doi.org/10.4155/ppa-2020-0028","url":null,"abstract":"<p><p>The alteration of mRNA translation has a crucial role in defining the changes in cellular proteome. The phosphorylation of eukaryotic initiation factor 4E by mitogen-activated protein kinase-interacting kinases (Mnks) leads to the release and translation of mRNAs of specific oncogenic proteins. In recent years, the efforts made by the pharmaceutical industry to develop novel chemical skeletons to create potent and selective Mnk inhibitors have been fruitful. The pyridone-aminal scaffold has been utilized to generate several series of Mnk inhibitors presented in multiple patent applications and research articles. Tomivosertib (eFT508) is one of the molecules with such scaffold. It is one of the first two Mnk inhibitors that entered clinical trials, and has displayed momentous activity against several solid and hematological cancers. The present compilation provides a succinct review of the current state of development of pyridone-aminal-derived Mnk inhibitors through the analysis of relevant patent applications filed in the last 5 years.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38749867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Repurposing drugs during the COVID-19 pandemic and beyond. 在 COVID-19 大流行期间及其后重新设计药物用途。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-15 DOI: 10.4155/ppa-2020-0031
Srividya Ravi, Sammita Jadhav, Anuradha Vaidya, Ravindra Ghooi
{"title":"Repurposing drugs during the COVID-19 pandemic and beyond.","authors":"Srividya Ravi, Sammita Jadhav, Anuradha Vaidya, Ravindra Ghooi","doi":"10.4155/ppa-2020-0031","DOIUrl":"10.4155/ppa-2020-0031","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38819726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patents in dengue disease management. 登革热疾病管理方面的最新专利。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-12-01 Epub Date: 2020-12-22 DOI: 10.4155/ppa-2020-0012
Sukhbir K Shahid
{"title":"Recent patents in dengue disease management.","authors":"Sukhbir K Shahid","doi":"10.4155/ppa-2020-0012","DOIUrl":"https://doi.org/10.4155/ppa-2020-0012","url":null,"abstract":"<p><p>Dengue, an illness caused by four serotypes of the dengue virus is most prevalent in Asia and Latin America. Its manifestation varies from asymptomatic cases to severe forms and even deaths and is a growing health concern. Despite attempts to curtail it, the infection continues to intensify in endemic areas and spread to new areas of the world. Development of a safe and effective vaccine and a potent antiviral drug is ongoing but so far there has been no breakthrough. Nonetheless, researchers are carrying out studies with newer vaccine candidates and antiviral moieties, and some of these hold promise for the future. The current article describes the recent patents targeted at dengue control.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38740575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two drugs facing key patent expirations and potential generic entry from November 2020 to December 2020. 2020年11月至2020年12月，两种药物面临关键专利到期和可能进入仿制药市场。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-12-01 Epub Date: 2020-12-22 DOI: 10.4155/ppa-2020-0033
Yali Friedman
{"title":"Two drugs facing key patent expirations and potential generic entry from November 2020 to December 2020.","authors":"Yali Friedman","doi":"10.4155/ppa-2020-0033","DOIUrl":"https://doi.org/10.4155/ppa-2020-0033","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38740571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Prosecution Highway program in Brazil and second medical indication patents challenges. 巴西专利审查高速公路项目和第二医学指征专利挑战。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-12-01 Epub Date: 2020-12-04 DOI: 10.4155/ppa-2020-0024
Carlos A Suganuma, Erica Mano
{"title":"Patent Prosecution Highway program in Brazil and second medical indication patents challenges.","authors":"Carlos A Suganuma,&nbsp;Erica Mano","doi":"10.4155/ppa-2020-0024","DOIUrl":"https://doi.org/10.4155/ppa-2020-0024","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38673001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights June-July 2020. 专利要点 2020 年 6 月至 7 月。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2020-12-01 Epub Date: 2020-12-04 DOI: 10.4155/ppa-2020-0027
Hermann Am Mucke
{"title":"Patent highlights June-July 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2020-0027","DOIUrl":"10.4155/ppa-2020-0027","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38673458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective inhibitors of human lactate dehydrogenase A to fight against metabolic cancer: a patent landscape. 人类乳酸脱氢酶A选择性抑制剂对抗代谢性癌症:专利景观。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-12-01 Epub Date: 2020-12-04 DOI: 10.4155/ppa-2020-0025
Vinit Kumar, Reshma Rani
{"title":"Selective inhibitors of human lactate dehydrogenase A to fight against metabolic cancer: a patent landscape.","authors":"Vinit Kumar,&nbsp;Reshma Rani","doi":"10.4155/ppa-2020-0025","DOIUrl":"https://doi.org/10.4155/ppa-2020-0025","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38673453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patent highlights April-May 2020. 2020 年 4 月至 5 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2020-09-01 Epub Date: 2020-09-22 DOI: 10.4155/ppa-2020-0018
Hermann Am Mucke
{"title":"Patent highlights April-May 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2020-0018","DOIUrl":"10.4155/ppa-2020-0018","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38502607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three drugs facing key patent expirations and potential generic entry from September to October 2020. 2020年9月至10月，三种药物面临关键专利到期和可能进入仿制药市场。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-09-01 Epub Date: 2020-10-22 DOI: 10.4155/ppa-2020-0029
Yali Friedman
{"title":"Three drugs facing key patent expirations and potential generic entry from September to October 2020.","authors":"Yali Friedman","doi":"10.4155/ppa-2020-0029","DOIUrl":"https://doi.org/10.4155/ppa-2020-0029","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38620386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信